Hypothalamic neoplasm

disease
On this page

Also known as hypothalamic neoplasmshypothalamic tumorhypothalamic tumourhypothalamus neoplasmhypothalamus tumorhypothalamus tumourneoplasm of hypothalamusneoplasm of the hypothalamustumor of hypothalamustumor of the hypothalamustumour of hypothalamustumour of the hypothalamus

Summary

Hypothalamic neoplasm (MONDO:0006799) is a cancer and 3 clinical trials. Top therapeutic interventions include phentermine. A subtype of hypothalamic disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • Classification: Cancer
  • Clinical trials: 3

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical namehypothalamic neoplasm
Mondo IDMONDO:0006799
EFOEFO:1000979
MeSHD007029
DOIDDOID:3644
ICD-111383549237
NCITC3129
SNOMED CT254968009
UMLSC0020659
MedGen5717
Anatomy (UBERON)UBERON:0001898
Is cancer (heuristic)yes

Also known as: hypothalamic neoplasms · hypothalamic tumor · hypothalamic tumour · hypothalamus neoplasm · hypothalamus tumor · hypothalamus tumour · neoplasm of hypothalamus · neoplasm of the hypothalamus · tumor of hypothalamus · tumor of the hypothalamus · tumour of hypothalamus · tumour of the hypothalamus

Disease family

An umbrella term covering 1 Mondo subtype.

Classification path: disease › human disease › disease by body system or component › nervous system disordercentral nervous system disorderbrain disorder › thalamic disorder › hypothalamic disorder › hypothalamic neoplasm

Related subtypes (2): Froelich syndrome, hypothalamic dysfunction

Subtypes (1): pituitary tumor

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

2 approved. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

DrugDevelopment status
CabergolineApproved (phase 4)
IopamidolApproved (phase 4)

Clinical trials & evidence

Clinical trials

Clinical trials: 3.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified2
PHASE21

Top trials by phase / activity

NCTPhaseStatusTitle
NCT06299891PHASE2RECRUITINGEfficacy and Safety of Phentermine/Topiramate in Youth With Hypothalamic Obesity
NCT07396896Not specifiedRECRUITINGKETO-TUMOR: a Study on Brain Tumors and Central Obesity
NCT03137615Not specifiedCOMPLETEDThe Cardiovascular Changes Associated With Septal Local Anaesthesia

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
PHENTERMINE43